RxDoctor Payments Data

Mark Adkins

Acute Care · Milton, WVNPI 1003831017

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 43.2% of the total. Reporting peaked in 2023 at $309 and has fallen 64.5% since, to $110 in 2025.

$958in general payments, 2019–2025

Across 67 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$414
  • Johnson & Johnson$161
  • Boston Scientific$158
  • Novartis$65
  • Biohaven Pharmaceutical Holding Company Ltd.$33
  • Medtronic$25
  • plus $103 from 6 others

What the payments were for

  • Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$958 in reported general payments places this provider in the 80th percentile of 51 acute care providers in West Virginia.

See all acute care providers in West Virginia

Medicare billing

Part B allowed, 2024
$24,772
Medicare patients
199
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$296,240
XareltoRivaroxaban139$184,443
EntrestoSacubitril/Valsartan29$45,991
Dofetilide79$27,417
MultaqDronedarone Hcl18$22,822
Flecainide Acetate208$9,098
Metoprolol Succinate288$5,171
SotalolSotalol Hcl136$2,709
Mexiletine Hcl21$2,198
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,310
Amiodarone Hcl59$1,048
Propafenone Hcl19$716
Digoxin28$493
Carvedilol46$261
Metoprolol Tartrate18$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$161$184,443139 claims
NovartisEntresto$65$45,99129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 51 acute care providers in West Virginia.

Other acute care in Milton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →